MDSL
CRL icon

M.D. Sass LLC’s Charles River Laboratories CRL Stock Holding History

M.D. Sass LLC’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-391,824
Closed -$72.3M – 34
2024
Q4 		$72.3M Buy
391,824
+70,652
+22% +$13.6M 5.44% 2
2024
Q3 		$63.3M Buy
321,172
+12,227
+4% +$2.54M 4.68% 10
2024
Q2 		$63.8M Buy
308,945
+159,492
+107% +$36.1M 4.58% 9
2024
Q1 		$40.5M Sell
149,453
-31,733
-18% -$7.58M 4.57% 9
2023
Q4 		$42.8M Sell
181,186
-3,268
-2% -$643K 5.15% 7
2023
Q3 		$36.1M Buy
184,454
+8,995
+5% +$1.85M 4.86% 5
2023
Q2 		$36.9M Buy
175,459
+25,288
+17% +$5.03M 4.89% 7
2023
Q1 		$30.3M Buy
150,171
+20,118
+15% +$4.56M 3.78% 10
2022
Q4 		$28.3M Sell
130,053
-8,361
-6% -$1.83M 4.16% 14
2022
Q3 		$27.2M Buy
+138,414
New +$29.9M 4.99% 9
2021
Q1 		– Sell
-39,841
Closed -$9.96M – 36
2020
Q4 		$9.96M Sell
39,841
-17,576
-31% -$4.19M 2.13% 21
2020
Q3 		$13M Sell
57,417
-14,328
-20% -$2.97M 3.22% 20
2020
Q2 		$12.5M Sell
71,745
-14,379
-17% -$2.29M 3.32% 18
2020
Q1 		$10.9M Buy
86,124
+9,523
+12% +$1.43M 3.95% 10
2019
Q4 		$11.7M Sell
76,601
-23,793
-24% -$3.29M 2.77% 21
2019
Q3 		$13.3M Buy
100,394
+54,014
+116% +$7.24M 3.14% 13
2019
Q2 		$6.58M Buy
+46,380
New +$6.29M 1.52% 27

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

M.D. Sass LLC's CRL Position: Q1 2025 in Review

M.D. Sass LLC sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 391,824 shares — an estimated $72.3M sold.

M.D. Sass LLC first reported a position in CRL in Q2 2019 and held it in 17 quarters. The position peaked at $72.3M in Q4 2024. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • M.D. Sass LLC reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • M.D. Sass LLC sold 391,824 Charles River Laboratories shares in Q1 2025, an estimated $72.3M.
  • M.D. Sass LLC first reported a position in Charles River Laboratories in Q2 2019 and held it in 17 quarters.
  • M.D. Sass LLC's Charles River Laboratories position peaked at $72.3M in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on M.D. Sass LLC's 13F filing for Q1 2025, filed 9 May 2025.